[Ip-health] Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis

Chris Redd reddchris40 at gmail.com
Sun Jan 22 05:02:36 PST 2017

Hello Everyone

We have recently published an article in BMJ Open regarding possible
generic prices for bortezomib, dasatinib, everolimus, and gefitinib,
medications that have been of limited availability in the UK due to cost.

The article can be found here: http://bmjopen.bmj.com/content/7/1/e011965


*Objectives* The aim of this study was to estimate lowest possible
treatment costs for four novel cancer drugs, hypothesising that generic
manufacturing could significantly reduce treatment costs.

*Setting:* This research was carried out in a non-clinical research setting
using secondary data.

*Participants:* There were no human participants in the study. Four drugs
were selected for the study: bortezomib, dasatinib, everolimus and
gefitinib. These medications were selected according to their clinical
importance, novel pharmaceutical actions and the availability of generic
price data.

*Primary and secondary outcome measures:* Target costs for treatment were
to be generated for each indication for each treatment. The primary outcome
measure was the target cost according to a production cost calculation
algorithm. The secondary outcome measure was the target cost as the lowest
available generic price; this was necessary where export data were not
available to generate an estimate from our cost calculation algorithm.
Other outcomes included patent expiry dates and total eligible treatment

*Results: *Target prices were £411 per cycle for bortezomib, £9 per month
for dasatinib, £852 per month for everolimus and £10 per month for
gefitinib. Compared with current list prices in England, these target
prices would represent reductions of 74–99.6%. Patent expiry dates were
bortezomib 2014–22, dasatinib 2020–26, everolimus 2019–25 and gefitinib
2017. The total global eligible treatment population in 1 year is 769 736.

*Conclusions:* Our findings demonstrate that affordable drug treatment
costs are possible for novel cancer drugs, suggesting that new therapeutic
options can be made available to patients and doctors worldwide. Assessing
treatment cost estimations alongside cost-effectiveness evaluations is an
important area of future research


Chris Redd

More information about the Ip-health mailing list